Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omega-3 carboxylic acids - AstraZeneca

Drug Profile

Omega-3 carboxylic acids - AstraZeneca

Alternative Names: AZD 0585; D-5884; DHA/EPA - AstraZeneca; Docosahexaenoic acid/eicosapentaenoic acid - AstraZeneca; Eicosapentaenoic acid/docosahexaenoic acid - AstraZeneca; EPA/DHA - AstraZeneca; Epanova; Omefas; Purepa

Latest Information Update: 29 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tillotts Pharma
  • Developer AstraZeneca; Cleveland Clinic; Tillotts Pharma
  • Class Antihyperlipidaemics; Carboxylic acids; Docosahexaenoic acids; Eicosanoids; Omega 3 fatty acids; Omega-6 fatty acids
  • Mechanism of Action Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Hypertriglyceridaemia
  • Phase II Non-alcoholic fatty liver disease
  • No development reported Cardiovascular disorders
  • Discontinued Crohn's disease

Most Recent Events

  • 04 Dec 2019 AstraZeneca intends to submit regulatory application for Hypertriglyceridaemia in 2021
  • 28 Oct 2019 No recent reports of development identified for research development in Cardiovascular-disorders(Prevention) in USA (PO, Capsule)
  • 24 Oct 2019 AstraZeneca completes enrolment in the phase III STRENGTH trial for Hypertriglyceridaemia in the US, Australia, New Zealand, Canada, the UK, Belgium, Estonia, Czech Republic, Denmark, Hungary, Italy, Lithuania, Netherlands, Poland, South Africa, Japan, South Korea, Taiwan, Russia and Ukraine, China, Mexico (PO)(NCT02104817) (EudraCT2014-001069-28)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top